Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

CTI BioPharma Corp. (CTIC)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
5.79+0.04 (+0.70%)
At close: 01:00PM EST
5.78 -0.01 (-0.26%)
After hours: 03:03PM EST
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Double Moving Average Crossover

Double Moving Average Crossover

Previous Close5.75
Open5.72
Bid5.80 x 3200
Ask5.84 x 3200
Day's Range5.51 - 5.85
52 Week Range1.43 - 7.80
Volume998,954
Avg. Volume3,866,498
Market Cap734.716M
Beta (5Y Monthly)0.79
PE Ratio (TTM)N/A
EPS (TTM)-1.23
Earnings DateNov 07, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est11.08
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for CTIC

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • CTI BioPharma Corp.
    Analyst Report: Incyte CorporationIncyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
    Rating
    Fair Value
    Economic Moat
    25 days agoMorningstar
View more
Advertisement
Advertisement